MA47356B1 - Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases - Google Patents

Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases

Info

Publication number
MA47356B1
MA47356B1 MA47356A MA47356A MA47356B1 MA 47356 B1 MA47356 B1 MA 47356B1 MA 47356 A MA47356 A MA 47356A MA 47356 A MA47356 A MA 47356A MA 47356 B1 MA47356 B1 MA 47356B1
Authority
MA
Morocco
Prior art keywords
kinases
phosphoinositide
inhibitors
derivatives useful
isochromene
Prior art date
Application number
MA47356A
Other languages
English (en)
Other versions
MA47356A1 (fr
Inventor
Matteo Biagetti
Anna Maria Capelli
Alessandro Accetta
Laura Carzaniga
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA47356A1 publication Critical patent/MA47356A1/fr
Publication of MA47356B1 publication Critical patent/MA47356B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des composés qui inhibent les phosphoinositide 3-kinases (pi3k), des compositions pharmaceutiques comprenant ces composés et l'utilisation thérapeutique de celles-ci dans le traitement des maladies associées aux enzymes pi3k.
MA47356A 2013-12-18 2014-12-17 Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases MA47356B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13197986 2013-12-18
PCT/EP2014/078288 WO2015091685A1 (fr) 2013-12-18 2014-12-17 Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases

Publications (2)

Publication Number Publication Date
MA47356A1 MA47356A1 (fr) 2020-10-28
MA47356B1 true MA47356B1 (fr) 2021-03-31

Family

ID=49841547

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47356A MA47356B1 (fr) 2013-12-18 2014-12-17 Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases

Country Status (34)

Country Link
US (1) US9321776B2 (fr)
EP (1) EP3083617B1 (fr)
JP (1) JP6617973B2 (fr)
KR (1) KR102371570B1 (fr)
CN (1) CN105829308B (fr)
AR (1) AR098776A1 (fr)
AU (1) AU2014368725B2 (fr)
CA (1) CA2934135C (fr)
CL (1) CL2016001543A1 (fr)
CY (1) CY1122098T1 (fr)
DK (1) DK3083617T3 (fr)
EA (1) EA035173B1 (fr)
ES (1) ES2755355T3 (fr)
GE (1) GEP20196954B (fr)
HR (1) HRP20192151T1 (fr)
HU (1) HUE046470T2 (fr)
IL (1) IL246263B (fr)
LT (1) LT3083617T (fr)
MA (1) MA47356B1 (fr)
MX (1) MX370900B (fr)
MY (1) MY181602A (fr)
PE (1) PE20160689A1 (fr)
PH (1) PH12016501160A1 (fr)
PL (1) PL3083617T3 (fr)
PT (1) PT3083617T (fr)
RS (1) RS59720B1 (fr)
SA (1) SA516371350B1 (fr)
SG (1) SG11201604908UA (fr)
SI (1) SI3083617T1 (fr)
TN (1) TN2016000245A1 (fr)
TW (1) TWI672297B (fr)
UA (1) UA120751C2 (fr)
WO (1) WO2015091685A1 (fr)
ZA (1) ZA201604084B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
MX2016004340A (es) 2013-10-04 2016-08-08 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017134053A1 (fr) 2016-02-04 2017-08-10 Chiesi Farmaceutici S.P.A. Dérivés de pyrazole à utiliser en tant qu'inhibiteurs de phosphoinositide 3-kinases
WO2017161116A1 (fr) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108623573A (zh) * 2017-03-16 2018-10-09 河北农业大学 一种异香豆素衍生物及其合成方法
GB201706102D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
KR20210086614A (ko) 2018-10-30 2021-07-08 치에시 파마슈티시 에스.피.아. 기계 호흡중인 환자에게 약물을 투여하는 장치
MA55479A (fr) 2019-04-04 2022-02-09 Chiesi Farm Spa Dérivés d'isochromène utilisés en tant qu'inhibiteurs de phosphoinositide 3-kinases
CA3150240A1 (fr) 2019-09-24 2021-04-01 Tomaso GUIDI Formulation de poudre seche pour un inhalateur a poudre seche comprenantune combinaison de particules spheronisees et de particules grossieres, et inhalateur a poudre seche comprenant la formulation
CN114195818B (zh) * 2021-12-24 2023-11-24 盐城工学院 一种4-芳硫基香豆素类化合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0597841A (ja) * 1991-10-04 1993-04-20 Mercian Corp イソクマリン誘導体
JP3724818B2 (ja) * 1992-09-04 2005-12-07 武田薬品工業株式会社 縮合複素環化合物、その製造法および剤
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
JP2002161091A (ja) * 2000-11-28 2002-06-04 Mercian Corp 気管支拡張剤
WO2004031171A1 (fr) * 2002-10-01 2004-04-15 Mitsubishi Pharma Corporation Composes d'isoquinoline et leur utilisation medicinale
JP5869222B2 (ja) * 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
AP2012006294A0 (en) * 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
EP2705029B1 (fr) * 2011-05-04 2018-10-24 Rhizen Pharmaceuticals S.A. Nouveaux composés en tant que modulateurs de protéines kinases
CA2842190A1 (fr) * 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Composes heterocycliques et leurs utilisations
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
WO2016166329A1 (fr) * 2015-04-17 2016-10-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Analyse par cytométrie en flux pour mesurer l'adhésion des upec aux cellules épithéliales de la vessie

Also Published As

Publication number Publication date
JP2017501146A (ja) 2017-01-12
EA201691032A1 (ru) 2016-11-30
EP3083617A1 (fr) 2016-10-26
WO2015091685A1 (fr) 2015-06-25
TW201609714A (zh) 2016-03-16
HRP20192151T1 (hr) 2020-02-21
SI3083617T1 (sl) 2019-11-29
PT3083617T (pt) 2019-11-20
MY181602A (en) 2020-12-29
MX370900B (es) 2020-01-09
LT3083617T (lt) 2019-11-25
DK3083617T3 (da) 2019-10-28
CA2934135A1 (fr) 2015-06-25
US9321776B2 (en) 2016-04-26
PE20160689A1 (es) 2016-07-28
CN105829308B (zh) 2019-03-08
PH12016501160A1 (en) 2016-08-15
ES2755355T3 (es) 2020-04-22
IL246263A0 (en) 2016-08-02
TWI672297B (zh) 2019-09-21
CN105829308A (zh) 2016-08-03
AU2014368725B2 (en) 2019-03-07
SG11201604908UA (en) 2016-07-28
TN2016000245A1 (en) 2017-10-06
MA47356A1 (fr) 2020-10-28
GEP20196954B (en) 2019-03-11
MX2016007410A (es) 2016-09-08
JP6617973B2 (ja) 2019-12-11
HUE046470T2 (hu) 2020-03-30
NZ721242A (en) 2021-04-30
EP3083617B1 (fr) 2019-09-11
RS59720B1 (sr) 2020-01-31
SA516371350B1 (ar) 2019-08-07
PL3083617T3 (pl) 2020-02-28
CL2016001543A1 (es) 2017-01-13
CY1122098T1 (el) 2020-11-25
ZA201604084B (en) 2018-07-25
AU2014368725A1 (en) 2016-07-07
IL246263B (en) 2018-05-31
KR102371570B1 (ko) 2022-03-07
US20150166549A1 (en) 2015-06-18
EA035173B1 (ru) 2020-05-12
KR20160098420A (ko) 2016-08-18
UA120751C2 (uk) 2020-02-10
AR098776A1 (es) 2016-06-15
CA2934135C (fr) 2023-06-13

Similar Documents

Publication Publication Date Title
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA40290A1 (fr) Agents immunorégulateurs
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
BR112014026703A2 (pt) inibidores de dna-pk
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
TR201901886T4 (tr) DNA-PK inhibitörleri.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
MA38483A1 (fr) Inhibiteurs de l'ido
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
BR112016006388A2 (pt) inibidor seletivo da fosfatidilinositol 3-quinase gama
MA38925A1 (fr) Dérivés de phénylalanine substitués
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
CA2929436C (fr) Composes, composition pharmaceutique et methodes a utiliser dans le traitement de maladies inflammatoires
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
UY35745A (es) Derivados sustituidos de fenilalanina